Andrew J Ball PhD,
Andrew is a serial innovator and value creator in life sciences tools and assays. Â His goal is to develop technologies and platforms that provide new insights into the biology of human health and disease.
As Chief Executive Officer of SeromYx Systems, Inc., his mission is to enable the discovery and development of safer and more effective antibody therapeutics and vaccines for many of the world’s deadliest diseases.  SeromYx provides insights into immune function through the integration of advanced assay systems and computational analysis.
At Abcam, a Danaher company, Andrew led a global R&D organization developing and commercializing immunoassays, cell-based assays, antibody conjugates, recombinant proteins and contract assay services. He has also held roles as VP of Assay Development at Quanterix, developing ultrasensitive assays for detection of neurodegenerative disease. Â He was VP of R&D at Quad Technologies, a cell and gene therapy startup acquired by Bio-Techne, and has served in innovation and strategic leadership roles at MilliporeSigma. Andrew is also a member of the Northern Ireland Life Sciences Advisory Board
What Makes Them Innovative
Andrew has a track record creating new technologies which turn complex biology into actionable insights, pushing the boundaries of how biological systems are measured and understood. He believes that innovation frequently emerges at the intersections of technologies.  He  focuses on delivering breakthroughs in areas which have the potential to solve high-impact problems in human health, while leading organizations to systematically create new value.
